Mayo Foundation for Medical Education and Research (MFMER) and University of Florida have identified atrial natriuretic peptide B (NPR2; guanylate cyclase B) receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of fibrosis.
University of Michigan has disclosed prodrugs of stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer, autoimmune disease, inflammatory disorder and infections.
Otsuka Pharmaceutical Co. Ltd. has described macrophage colony-stimulating factor 1 receptor (CSF1R; CD115; c-Fms) inhibitors reported to be useful for diagnosis and treatment of pain, infections, amyotrophic lateral sclerosis, multiple sclerosis, cardiovascular disorders, Alzheimer’s disease and Parkinson’s disease, among others.
Eli Lilly & Co. has divulged aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of psoriasis, atopic dermatitis, ulcerative colitis, Crohn’s disease, graft-versus-host disease, rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis.
Bpgbio Inc. has synthesized bifunctional compounds comprising an E2 ubiquitin ligase binding ligand covalently linked to an estrogen receptor α (ER-α; ESR1) targeting moiety through a linker acting as ESR1 degradation inducers reported to be useful for the treatment of cancer.
Dong-A ST Co. Ltd. has disclosed transcriptional enhancer factor (TEAD) and/or transcriptional coactivator YAP1/TEAD interaction inhibitors reported to be useful for the treatment of cancer.
Enanta Pharmaceuticals Inc. has described 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of liver (hepatocellular carcinoma) cancer, cirrhosis, idiopathic pulmonary fibrosis and nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
RSS